Kumar Rakhi 4
4 · Roivant Sciences Ltd. · Filed Feb 18, 2025
Insider Transaction Report
Form 4
Kumar Rakhi
Chief Accounting Officer
Transactions
- Exercise/Conversion
Common Shares
2025-02-13$3.85/sh+187,500$721,875→ 390,764 total - Sale
Common Shares
2025-02-13$10.43/sh−227,500$2,372,825→ 163,264 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-13−187,500→ 312,500 totalExercise: $3.85Exp: 2032-04-19→ Common Stock (187,500 underlying)
Footnotes (2)
- [F1]The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- [F2]Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).